Viewing Study NCT02437760


Ignite Creation Date: 2025-12-25 @ 2:02 AM
Ignite Modification Date: 2026-03-01 @ 6:12 AM
Study NCT ID: NCT02437760
Status: UNKNOWN
Last Update Posted: 2015-05-08
First Post: 2015-04-18
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: The Prognostic and Predictive Value of the CA-125 Marker in Lung Cancer Monitoring
Sponsor: E-DA Hospital
Organization:

Study Overview

Official Title: Determination of the Prognostic and Predictive Value of the Cancer Antigen-125 (CA-125) Marker in Lung Cancer Monitoring
Status: UNKNOWN
Status Verified Date: 2015-05
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The tumor associated CA-125antigen for diagnosis and follow-up of ovarian cancer was well defined. Increased serum CA125 level may have many diagnoses other than ovarian cancer, including breast, colorectal and lung cancer. 80% lung cancer patients were diagnosed at advanced stage. Malignant pleural effusion secondary to lung cancer represented the condition of cancer cell involved pleura.

The CA-125 level may reflect the extent of tumor involved in pleura (tumor burden), it could be correlated with the prognosis. This study was performed to examine the properties of CA-125 by measuring pleural and blood CA-125 levels in lung cancer with or without malignant pleural effusion; meanwhile to examine whether the rate of decline in CA 125 during primary therapy as a surrogate indicator for survival.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: